A PATH TO CONTROL FOR DIFFERENT
PATIENT TYPES

Different Patients. One DUPIXENT.

Is a patient appropriate for DUPIXENT? Build a patient based on key clinical characteristics to find out.

Patients enrolled had elevations in multiple biomarkers, including eosinophils, IgE, and FeNO1

Examples of patients with an eosinophilic phenotype or with OCS-dependent asthma

Allergic Asthma Patient with Elevated Eosinophils
  • EOS 155 cells/µL
  • IgE 380 IU/mL

2 severe exacerbations in the past year
Compromised lung function:
70% FEV1 % predicted

  • Diagnosed with asthma as a child
  • Positive skin test to a perennial aeroallergen
  • Triple therapy: ICS/LABA + LTRA
EXPLORE EXACERBATION DATA
  • EOS 320 cells/µL
  • IgE 95 IU/mL
  • FeNO 40 ppb

2 severe exacerbations in the past year
Compromised lung function:
65% FEV1 % predicted

  • Diagnosed with adult-onset asthma at age 28
  • Lack of asthma control
  • Triple therapy: High-dose ICS/LABA + LAMA
EXPLORE LUNG FUNCTION DATA
  • EOS 140 cells/µL
  • IgE 405 IU/mL

2 severe exacerbations in the past year
Compromised lung function:
58% FEV1 % predicted

  • Diagnosed with adult-onset asthma at age 23
  • Lack of asthma control
  • Daily OCS use
  • Triple therapy: High-dose ICS/LABA + LTRA
EXPLORE OCS-DEPENDENT DATA

Patient profiles are representative and are not actual DUPIXENT patients.

LABA, long-acting beta agonist; LAMA, long-acting muscarinic antagonist; LTRA, leukotriene receptor antagonist.

References:

  1. DUPIXENT Prescribing Information.
  2. Wenzel S, Castro M, Corren J, et al. Dupilumab efficacy and safety in adults with uncontrolled persistent asthma despite use of medium-to-high-dose inhaled corticosteroids plus a long-acting β2 agonist: a randomised double-blind placebo-controlled pivotal phase 2b dose-ranging trial. Lancet. 2016;388(10039):31-44.
  3. Data on file, Sanofi US. QUEST CSR, 2017.
  4. Rabe KF, Nair P, Brusselle G, et al. Efficacy and safety of dupilumab in glucocorticoid-dependent severe asthma. N Engl J Med. 2018;378(26):2475-2485.